GRANISETRON (gran'i-se-tron) Kytril Classifications: gastrointestinal agent; antiemetic; 5-ht3 antagonist Prototype: Ondansetron Pregnancy Category: B |
1 mg tablets; 1 mg/mL injection
Granisetron is a selective serotonin (5-HT3) receptor antagonist. Serotonin receptors of the 5-HT3 type are located centrally in the chemoreceptor trigger zone, and peripherally on the vagal nerve terminals. Serotonin is released from the wall of the small intestine, stimulates the vagal afferent neurons through the serotonin (5-HT3) receptors, and initiates the vomiting reflex.
This selective serotonin (5-HT3) receptor antagonist is used for the prevention of nausea and vomiting associated with cancer chemotherapy.
Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin.
Hypersensitivity to granisetron.
Liver disease, pregnancy (category B), lactation, children <2 y.
Nausea and Vomiting Adult/Child: IV >2 y, 10 mcg/kg infused over 30 sec5 min, beginning at least 30 min before initiation of chemotherapy (up to 40 mcg/kg per dose has been used) PO 1 mg b.i.d., start 1 mg up to 1 h prior to chemotherapy, then second tab 12 h later or 2 mg q.d. |
Intravenous PREPARE: Direct: Give undiluted. IV Infusion: Dilute in NS or D5W to a total volume of 2050 mL. Prepare infusion at time of administration; do not mix in solution with other drugs. ADMINISTER: Direct: Give a single dose over 30 sec. IV Infusion: Infuse diluted drug over 5 min or longer; complete infusion 2030 min prior to initiation of chemotherapy. |
Assessment & Drug Effects
Patient & Family Education